Stella Diagnostics Inc.
Stella Diagnostics Inc.
Your view on SLDX
Overview
What the company does, where it operates, and who runs it.
About Stella Diagnostics Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- David Seaburg
- Headquarters
- 50 West Broadway, Salt Lake City, UT, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- David Seaburg
- Headquarters
- 50 West Broadway, Salt Lake City, UT, US
Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients' tissue to determine if the disease is stable, progressing, or turning cancerous.
The company is also developing diagnostic tools that provides molecular information for providers as compared to the screening protocols. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is based in Salt Lake City, Utah.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Stella Diagnostics Inc., and the rating behind it. SLDX last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Stella Diagnostics Inc.. Starting points for Stella Diagnostics Inc.: EPS -$0.01, beta 0.23 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Stella Diagnostics Inc.. Stella Diagnostics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Stella Diagnostics Inc.. Trailing twelve-month EPS for Stella Diagnostics Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Stella Diagnostics Inc.. Stella Diagnostics Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Stella Diagnostics Inc. valued side by side against its closest peers. Stella Diagnostics Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Stella Diagnostics Inc., and how their positions are changing. At a $1.4M market value, institutional positions materially move Stella Diagnostics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Stella Diagnostics Inc. executives and directors. Shares of Stella Diagnostics Inc. have traded between $0.01 and $0.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Stella Diagnostics Inc.. Stella Diagnostics Inc. is a $1.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Stella Diagnostics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Stella Diagnostics Inc.. Coverage tracks Stella Diagnostics Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.